Fig. 11
From: Molecularly imprinted polymers (MIPs): emerging biomaterials for cancer theragnostic applications
A Preparation procedure and therapeutic mechanism of programmed death-ligand 1 (PD-L1) peptide-imprinted composite nanoparticles (NPs). B Cellular viabilities of HePG2 cells incubated with various concentrations of non-imprinted polymers (NIPs) and molecularly imprinted polymers (MIPs). C Optical, 4′,6-diamidino-2-phenylindole (DAPI)-stained, and merged images of HepG2 cells treated with MIPs without and with NIR irradiation. D Schematic illustration for the preparation of MIPs@doxorubicin (DOX). E Live/dead cell staining assays under various treatments. F Relative tumor volume in 14 d with various treatments. The average tumor weight (G) and corresponding tumor tissues (H) after treatments for 14 d. I Synthetic procedure and photodynamic killing mechanism of two cyclopenta-dithiophene units and one boron dipyrromethene core as a photosensitizer, and poly(styrene-co-maleic anhydride) (PSMA) modified with phenylboronic acid as a polymer matrix (CB/PSMAB-SA NPs) toward sialic acid (SA) over-expressed cancer cells. J Cellular cytotoxicity of DU 145 cells after treatment with MIPs under normoxia or hypoxia along with light irradiation (660 nm, 0.1 W/cm.2). A, B, C Reproduced with permission from [163], published by MDPI 2021. D, E, F, G, H Reproduced with permission from [162], published by American Chemical Society 2020. I, J Reproduced with permission from [164], published by Wiley 2022